BR112012031136A2 - agentes anti-inflamatórios - Google Patents
agentes anti-inflamatóriosInfo
- Publication number
- BR112012031136A2 BR112012031136A2 BR112012031136A BR112012031136A BR112012031136A2 BR 112012031136 A2 BR112012031136 A2 BR 112012031136A2 BR 112012031136 A BR112012031136 A BR 112012031136A BR 112012031136 A BR112012031136 A BR 112012031136A BR 112012031136 A2 BR112012031136 A2 BR 112012031136A2
- Authority
- BR
- Brazil
- Prior art keywords
- inflammatory agents
- compounds
- aminolactoma
- formulas
- aromatic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D223/12—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
agentes anti-inflamatórios. são revelados aqui métodos de prevenir ou tratar doenças inflamatórias utilizando análogos de sulfonamida de compostos de 3-aminolactoma, cada com "grupos cauda" aromáticos. os compostos como definidos pela fórmulas (i) e (i) e os usos médicos dos compostos, são descritos aqui.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1009603.0A GB201009603D0 (en) | 2010-06-08 | 2010-06-08 | Anti-inflammatory agent |
PCT/GB2011/000862 WO2011154695A1 (en) | 2010-06-08 | 2011-06-08 | Anti-inflammatory agents |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012031136A2 true BR112012031136A2 (pt) | 2017-08-08 |
Family
ID=42471347
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012031136A BR112012031136A2 (pt) | 2010-06-08 | 2011-06-08 | agentes anti-inflamatórios |
BR112012030816A BR112012030816A2 (pt) | 2010-06-08 | 2011-06-08 | agentes antiinflamatórios |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012030816A BR112012030816A2 (pt) | 2010-06-08 | 2011-06-08 | agentes antiinflamatórios |
Country Status (20)
Country | Link |
---|---|
US (2) | US20130172318A1 (pt) |
EP (2) | EP2580197A1 (pt) |
JP (2) | JP2013531647A (pt) |
KR (2) | KR20130115082A (pt) |
CN (2) | CN103080090A (pt) |
AP (2) | AP2012006559A0 (pt) |
AU (1) | AU2011263531A1 (pt) |
BR (2) | BR112012031136A2 (pt) |
CA (2) | CA2798213A1 (pt) |
CL (1) | CL2012003460A1 (pt) |
CO (2) | CO6670569A2 (pt) |
GB (1) | GB201009603D0 (pt) |
IL (2) | IL222798A0 (pt) |
MA (2) | MA34369B1 (pt) |
MX (2) | MX2012014290A (pt) |
PE (2) | PE20131046A1 (pt) |
SG (2) | SG185130A1 (pt) |
TN (2) | TN2012000521A1 (pt) |
WO (2) | WO2011154696A1 (pt) |
ZA (2) | ZA201208367B (pt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MD4788C1 (ro) * | 2017-09-07 | 2022-09-30 | Ооо "Валента-Интеллект" | Utilizarea derivatului de glutarimidă pentru tratarea afecţiunilor, legate de activitatea aberantă a citokinelor |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3054738B2 (ja) * | 1988-07-22 | 2000-06-19 | 武田薬品工業株式会社 | チアゾロ[5,4―b]アゼピン誘導体 |
JPH03206042A (ja) | 1990-01-06 | 1991-09-09 | Takeda Chem Ind Ltd | 降圧剤 |
IT1247698B (it) | 1990-06-21 | 1994-12-30 | Sigma Tau Ind Farmaceuti | 1-alchil-3-(acilammino)-e-caprolattami quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti |
DE4117507A1 (de) * | 1991-05-24 | 1992-11-26 | Schering Ag | Verfahren zur herstellung von n(pfeil hoch)6(pfeil hoch)-substituierten lysin-derivaten |
JP3206042B2 (ja) | 1991-10-31 | 2001-09-04 | ミノルタ株式会社 | 新規トリアミノ化合物を用いた電荷輸送材料、このトリアミノ化合物を含有する感光体およびエレクトロルミネセンス素子 |
US6989435B2 (en) | 1997-09-11 | 2006-01-24 | Cambridge University Technical Services Ltd. | Compounds and methods to inhibit or augment an inflammatory response |
AU2610000A (en) | 1999-01-12 | 2000-08-01 | Cambridge University Technical Services Limited | Compounds and methods to inhibit or augment an inflammatory response |
AU2003269850A1 (en) * | 2002-10-08 | 2004-05-04 | Novo Nordisk A/S | Hemisuccinate salts of heterocyclic dpp-iv inhibitors |
US7674797B2 (en) * | 2003-03-24 | 2010-03-09 | Axikin Pharmaceuticals, Inc. | 2-phenoxy- and 2-phenylsulfonamide derivatives with CCR3 antagonistic activity for the treatment of asthma and other inflammatory or immunological disorders |
WO2005042489A1 (en) | 2003-10-29 | 2005-05-12 | Elan Pharmaceuticals, Inc. | N-substituted benzene sulfonamides |
CN103393691A (zh) | 2003-12-01 | 2013-11-20 | 剑桥企业有限公司 | 抗炎药 |
AU2005261932B2 (en) | 2004-07-13 | 2011-10-13 | F. Hoffmann-La Roche Ag | Sulfonamide derivatives |
GB2418425B (en) * | 2004-08-11 | 2008-09-03 | Univ Cambridge Tech | Anti-inflammatory agents |
GB2418426A (en) | 2004-08-18 | 2006-03-29 | Univ Cambridge Tech | Alpha-(acylamino)-bicyclolactam derivatives for treatment of inflammatory disorders |
GB2423085C (en) | 2005-02-11 | 2011-11-09 | Cambridge Entpr Ltd | Ligands for G-protein coupled receptors |
GB0512238D0 (en) | 2005-06-15 | 2005-07-27 | Univ Cambridge Tech | Anti-inflammatory agents |
EP1896036B1 (en) * | 2005-06-15 | 2013-01-23 | Cambridge Enterprise Limited | Anti-inflammatory agents |
DE602006019103D1 (de) | 2005-08-12 | 2011-02-03 | Hoffmann La Roche | Fluorsubstituierte 2-oxo-azepan-derivate |
ATE534293T1 (de) | 2005-09-27 | 2011-12-15 | Irm Llc | Diarylaminhaltige verbindungen und zusammensetzungen und deren verwendung als modulatoren von c-kit-rezeptoren |
US20110038885A1 (en) | 2007-07-26 | 2011-02-17 | Zheng Xin Dong | Chemokine analogs |
GB2452696B (en) | 2007-08-02 | 2009-09-23 | Cambridge Entpr Ltd | 3-(2',2'-dimethylpropanoylamino)-tetrahydropyridin-2-one and its use in pharmaceutical compositions |
-
2010
- 2010-06-08 GB GBGB1009603.0A patent/GB201009603D0/en not_active Ceased
-
2011
- 2011-06-08 CN CN2011800286501A patent/CN103080090A/zh active Pending
- 2011-06-08 SG SG2012081675A patent/SG185130A1/en unknown
- 2011-06-08 CA CA2798213A patent/CA2798213A1/en not_active Abandoned
- 2011-06-08 MA MA35547A patent/MA34369B1/fr unknown
- 2011-06-08 MX MX2012014290A patent/MX2012014290A/es unknown
- 2011-06-08 JP JP2013513742A patent/JP2013531647A/ja not_active Withdrawn
- 2011-06-08 BR BR112012031136A patent/BR112012031136A2/pt not_active IP Right Cessation
- 2011-06-08 AP AP2012006559A patent/AP2012006559A0/xx unknown
- 2011-06-08 US US13/702,898 patent/US20130172318A1/en not_active Abandoned
- 2011-06-08 KR KR1020127031173A patent/KR20130115082A/ko not_active Application Discontinuation
- 2011-06-08 WO PCT/GB2011/000863 patent/WO2011154696A1/en active Application Filing
- 2011-06-08 JP JP2013513741A patent/JP2013528201A/ja not_active Withdrawn
- 2011-06-08 AU AU2011263531A patent/AU2011263531A1/en not_active Abandoned
- 2011-06-08 WO PCT/GB2011/000862 patent/WO2011154695A1/en active Application Filing
- 2011-06-08 AP AP2012006560A patent/AP2012006560A0/xx unknown
- 2011-06-08 CN CN201180028686XA patent/CN103119021A/zh active Pending
- 2011-06-08 PE PE2012002286A patent/PE20131046A1/es not_active Application Discontinuation
- 2011-06-08 PE PE2012002288A patent/PE20130772A1/es not_active Application Discontinuation
- 2011-06-08 EP EP11725489.6A patent/EP2580197A1/en not_active Withdrawn
- 2011-06-08 SG SG2012081667A patent/SG185129A1/en unknown
- 2011-06-08 EP EP11725490.4A patent/EP2580196A1/en not_active Withdrawn
- 2011-06-08 MA MA35548A patent/MA34370B1/fr unknown
- 2011-06-08 KR KR1020127033497A patent/KR20130086952A/ko not_active Application Discontinuation
- 2011-06-08 CA CA2798129A patent/CA2798129A1/en not_active Abandoned
- 2011-06-08 MX MX2012014291A patent/MX2012014291A/es unknown
- 2011-06-08 BR BR112012030816A patent/BR112012030816A2/pt not_active IP Right Cessation
- 2011-06-08 US US13/702,872 patent/US20130203734A1/en not_active Abandoned
-
2012
- 2012-10-31 TN TNP2012000521A patent/TN2012000521A1/en unknown
- 2012-11-01 IL IL222798A patent/IL222798A0/en unknown
- 2012-11-02 TN TNP2012000525A patent/TN2012000525A1/en unknown
- 2012-11-05 IL IL222866A patent/IL222866A0/en unknown
- 2012-11-07 ZA ZA2012/08367A patent/ZA201208367B/en unknown
- 2012-11-08 ZA ZA2012/08406A patent/ZA201208406B/en unknown
- 2012-12-07 CL CL2012003460A patent/CL2012003460A1/es unknown
-
2013
- 2013-01-08 CO CO13002648A patent/CO6670569A2/es not_active Application Discontinuation
- 2013-01-08 CO CO13002653A patent/CO6670553A2/es not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1124742T1 (el) | 4'-φθορο-νουκλεοσιδια, 4'-φθορο-νουκλοεοτιδια και αναλογα αυτων για τη θεραπευτικη αγωγη toy hcv | |
CY1120337T1 (el) | Θειοοξικες ενωσεις, συνθεσεις και μεθοδοι χρησης | |
CY1119056T1 (el) | Παραγωγα 2',4',-διφθορο-2'-μεθυλ υποκατεστημενου νουκλεοσιδιου ως αναστολεις αντιγραφης hcv rna | |
EA201990665A1 (ru) | Регуляторы hpk1 на основе производных пиразолопиридина и их применение для лечения рака | |
BR112017011923A2 (pt) | bactéria modificada para tratar doenças associadas com hiperamonemia | |
EA201791916A1 (ru) | 2'-замещенные карбануклеозидные аналоги для противовирусного лечения | |
BR112015018508A2 (pt) | moduladores de enzimas modificadoras de metila, suas composições e uso | |
BR112014026703A2 (pt) | inibidores de dna-pk | |
BR112015024078A2 (pt) | derivados de benzimidazolona como inibidores de bromodomínio | |
ECSP13013068A (es) | Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2 | |
BR112016025423A2 (pt) | compostos e composições como agonistas de receptores do tipo toll 7 | |
EA201490042A1 (ru) | Азетидинил-фенил-, пиридил- или пиразинилкарбоксамидные производные как ингибиторы jak | |
EA201590850A1 (ru) | Трициклические конденсированные производные тиофена как ингибиторы jak | |
ECSP13013024A (es) | 1,3-oxazinas como inhibidores de bace1 y/o bace2 | |
EA201201648A1 (ru) | Стимуляторы sgc | |
BR112013005872A2 (pt) | compostos, composição farmacêutica e respectivos usos | |
BR112012030711A2 (pt) | derivado de purinona | |
BR112014031730A2 (pt) | entidades químicas, composições farmacêuticas, compostos ou sais farmaceuticamente aceitáveis dos mesmos, usos de entidades químicas ou composições e métodos para tratar doenças, distúrbios ou condições médicas mediadas pela atividade enzimática de pde1 e para modular a atividade da enzima pde1 | |
EA201201661A1 (ru) | Новые аминопиразолохиназолины | |
BR112014027981A2 (pt) | compostos do tipo fumagilol e métodos de produção e utilização dos mesmos | |
UY33349A (es) | Nuevos compuestos de quinoxalina, quinolina y quinazolina, composiciones farmacéuticas que los contienen y uso de los mismos | |
BR112018071602A2 (pt) | compostos de imidazopiridina substituídos como inibidores da indolamina 2,3-dioxigenase e/ou triptofano-2,3-dioxigenase | |
BR112017001334A2 (pt) | compostos de imidazopiridazina, seu uso e composição farmacêutica que os compreende | |
EA201400623A1 (ru) | Новые 2h-индазолы в качестве антагонистов рецептора ep | |
BR112016028888A2 (pt) | compostos que compreendem o sistema 1,1',2,5'-tetra hidro espiro [indol-3,2'-pirrol]-2,5'-diona como inibidores de interação proteína-proteína p53-mdm2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B15I | Others concerning applications: loss of priority | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2433 DE 22-08-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |